摘要
以金属为基础的药物,也被称为“metallopharmaceuticals”或“metallodrugs”,都是复杂的化合物且已被作为治疗药物长期应用于无机药物化学中。其中一些展现了非常良好的前景,并且许多已被用于不同阶段的临床试验。在过去,钼金属药物被成功应用于治疗如贫血或威尔森疾病。此外,钼复合物被认为具有插入或切割DNA或RNA,捕获细胞周期,和改变细胞膜功能的作用。然而,在目前的文献中,没有可靠的、深入的综述阐述关于所有已知的钼复合物作为metallopharmaceuticals或metallodrugs的假设性治疗应用。主要强调的是关于深层次的综述钼复合物作为metallopharmaceuticals在治疗癌症,肿瘤,威尔森病,糖尿病,亨廷顿病,动脉硬化,贫血疾病等医药化学方面潜在的应用。必须强调的是,现今的钼类药品的创新发展不是很快速,因此,本文同时是为了激励工作在钼化合物这个领域并正试图找到“路标”的研究人员。作者希望这篇文章能够增加人们的对钼化合物的兴趣,并发起钼化合物在无机化学家中的复兴。本文是第一篇涉及到并强调钼金属药物在许多不同的和复杂的方面可能的应用及功能。
关键词: Cancer drugs
Current Medicinal Chemistry
Title:Molybdenum Metallopharmaceuticals Candidate Compounds - The “Renaissance” of Molybdenum Metallodrugs?
Volume: 23 Issue: 29
Author(s): Anna Jurowska, Kamil Jurowski, Janusz Szklarzewicz, Boguslaw Buszewski, Tatiana Kalenik, Wojciech Piekoszewski
Affiliation:
关键词: Cancer drugs
摘要: Metal-based drugs, also called “metallopharmaceuticals” or “metallodrugs”, are examples of sophisticated compounds that have been used in inorganic medicinal chemistry as therapeutic agents for a long time. Few of them have shown substantially promising results and many of them have been used in different phases of clinical trials. The Mo-based metallodrugs were successfully applied in the past for treating conditions such as anemia or Wilson’s disease. Moreover, Mo complexes are supposed to exert their effect by intercalation/ cleavage of DNA/RNA, arrest of the cell cycle, and alteration of cell membrane functions. However, in the current literature, there are no reliable and in-depth reviews about the hypothetical therapeutic applications of all of the known molybdenum complexes as metallopharmaceuticals/ metallodrugs. The main emphasis was on the in-depth review of the potential applications of Mo-based complexes in medicinal chemistry as metallopharmaceuticals in treating diseases such as cancer and tumors, Wilson’s disease, diabetes mellitus, Huntington’s disease, atherosclerosis, and anemia. It must be emphasized that today the development of innovative and new Mo-based metalo-pharmaceuticals is not rapid, and hence the aim of this paper was also to inspire colleagues working in the field of Mo compounds who are trying to find “signpost” for research. The authors hope that this article will increase interest and initiate the Renaissance of Mo-compounds among medicinal inorganic chemists. This paper is the first review article in the literature that refers to and emphasizes many different and complex aspects of possible applications and capabilities of Mo-based metallodrugs.
Export Options
About this article
Cite this article as:
Anna Jurowska, Kamil Jurowski, Janusz Szklarzewicz, Boguslaw Buszewski, Tatiana Kalenik, Wojciech Piekoszewski , Molybdenum Metallopharmaceuticals Candidate Compounds - The “Renaissance” of Molybdenum Metallodrugs?, Current Medicinal Chemistry 2016; 23 (29) . https://dx.doi.org/10.2174/0929867323666160504103743
DOI https://dx.doi.org/10.2174/0929867323666160504103743 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements